# VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.

Study · id `cardio:ct-nct03686306` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03686306](<https://clinicaltrials.gov/study/NCT03686306>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03686306

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 106 participants.

## Technical summary

Registry record NCT03686306. Randomized; triple masking; primary purpose treatment. Start 2021-11-24 (actual); primary completion 2025-11-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 106 participants (enrolled count; ClinicalTrials.gov record NCT03686306, source copy `cardio:ctgov-nct03686306-2025-06-24`, retrieved 2026-10-31)
- Started: 2021-11-24 (actual) (ClinicalTrials.gov record NCT03686306, source copy `cardio:ctgov-nct03686306-2025-06-24`, retrieved 2026-10-31)
- Primary completion: 2025-11-24 (anticipated) (ClinicalTrials.gov record NCT03686306, source copy `cardio:ctgov-nct03686306-2025-06-24`, retrieved 2026-10-31)
- Completion: 2026-06-24 (anticipated) (ClinicalTrials.gov record NCT03686306, source copy `cardio:ctgov-nct03686306-2025-06-24`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT03686306, source copy `cardio:ctgov-nct03686306-2025-06-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03686306-2025-06-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.
- Acronym: VIRTUOSE
- Condition: Peripheral Artery Disease
- Intervention (Drug): Sildenafil
- Intervention (Drug): Placebo
- Lead sponsor: Rennes University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Rennes University Hospital (`cardio:org-rennes-university-hospital`)

## Provenance

Content hash: 57f90c75b9e607c125358aa87efb4d7bb44378bf381589b4c99ca0456dd2689b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
